ERNA logo

Ernexa Therapeutics Inc.

ERNA
Healthcare|Biotechnology|US
$1.88
+0.05 (+2.73%)
DCF Value
$1.86
Tangible Book / Share
$2.79
Cash / Share
$3.57
Next Earnings Report
Mar 12, 2027
EPS est. -$4.76
Financing Filings (last 12 months)
6
Shelf registrations / offering prospectuses — latest Mar 24, 2026 (S-3/A). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Recent Press Releases

Ernexa Therapeutics Highlights ERNA-101's Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
Oct 22, 2026 · GlobeNewsWire
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Oct 12, 2026 · GlobeNewsWire
Ernexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
Oct 6, 2026 · GlobeNewsWire
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
Oct 1, 2026 · GlobeNewsWire
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
Sep 30, 2026 · GlobeNewsWire
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
Sep 29, 2026 · GlobeNewsWire
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D.
Sep 17, 2026 · GlobeNewsWire
Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing
Sep 15, 2026 · GlobeNewsWire
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 14, 2026 · GlobeNewsWire
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Aug 27, 2026 · GlobeNewsWire

SEC Filings (85)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 6, 202610-QQuarterly reportDocumentIndex
Oct 30, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Oct 15, 20268-KMaterial eventDocumentIndex
Sep 16, 20268-KMaterial eventDocumentIndex
Sep 16, 20268-KMaterial eventDocumentIndex
Aug 6, 202610-QQuarterly reportDocumentIndex
Jul 2, 20268-KMaterial eventDocumentIndex
Jul 2, 20268-KMaterial eventDocumentIndex
Jun 26, 20268-KMaterial eventDocumentIndex
May 20, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 14, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 11, 2026ARSAnnual report to holdersDocumentIndex
May 11, 2026DEFA14AProxy / shareholder voteDocumentIndex
May 11, 2026DEF 14AProxy / shareholder voteDocumentIndex
May 11, 202610-QQuarterly reportDocumentIndex
May 4, 20268-KMaterial eventDocumentIndex
Apr 13, 2026DEF 14CDocumentIndex
Apr 1, 2026PRE 14CDocumentIndex
Mar 30, 2026EFFECTDocumentIndex
Mar 24, 2026S-3/AShelf registrationDocumentIndex
Mar 20, 20268-KMaterial eventDocumentIndex
Mar 16, 2026S-3Shelf registrationDocumentIndex
Mar 13, 202610-KAnnual reportDocumentIndex
Feb 26, 20268-KMaterial eventDocumentIndex
Feb 17, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Feb 11, 20268-KMaterial eventDocumentIndex
Feb 10, 2026424B5Offering prospectusDocumentIndex
Feb 5, 2026EFFECTDocumentIndex
Feb 5, 2026CERTDocumentIndex
Feb 5, 20268-A12BDocumentIndex
Feb 5, 2026S-1/AIPO / offering registrationDocumentIndex
Feb 4, 2026S-1/AIPO / offering registrationDocumentIndex
Feb 3, 2026S-1IPO / offering registrationDocumentIndex
Dec 19, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Dec 16, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Dec 11, 20258-KMaterial eventDocumentIndex